FindTrial
Sign In

A CROSS-SECTIONAL STUDY ON PRURITUS IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF HEMATOLOGICAL MALIGNANCIES AND ITS ASSOCIATION WITH SERUM IL-13 LEVELS.

PRURITUS AND IT’S SEVERITY, CORRELATING WITH SERUM IL-31 LEVELS IN A STUDY ON CUTANEOUS MANIFESTATIONS OF HEMATOLOGICAL MALIGNANCIES : A CROSS-SECTIONAL STUDY IN A TERTIARY CARE CENTRE. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062463
Enrollment
87
Registered
2024-02-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L298- Other pruritus

Interventions

Intervention1: NIL: NIL

Sponsors

NIDHI P M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All diagnosed patients of hematological malignancies.

Exclusion criteria

Exclusion criteria: 1.Patients with hematological malignancies who also have dermatological disorders that are known to be associated with pruritus such as atopic dermatitis, allergic contact dermatitis, prurigo nodularis, chronic urticaria. 2. Patients testing positive for HIV 1 & 2, Hepatitis A and Hepatitis B. 3. Patients with diagnosed drug reactions. 4. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
-To recognise various cutaneous manifestations in hematological malignancies.Timepoint: 1 year 6 months—

Secondary

MeasureTime frame
-To know if there is any difference in serum IL-31 in Group-A ( Non itch) and Group-B (Itch group). -To observe whether the severity of pruritus in Group-B patients correlates with their serum IL-31 levels.Timepoint: 1 year 6 months—

Countries

India

Contacts

Public ContactT K SUMATHY

M S RAMAIAH MEDICAL COLLEGE

tksumathy@gmail.com9845163009

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026